Bedrijfsoverzicht
Supernus Pharmaceuticals, Inc. is a biopharmaceutical entity dedicated to the research, development, and commercialization of therapeutic products designed for the treatment of central nervous system (CNS) diseases within the United States market. The company operates within the broader Healthcare sector, specifically categorized under the industry of Drug Manufacturers - Specialty & Generic, which implies a focus on specialized pharmaceutical formulations rather than mass-market generic drugs. This organization maintains a workforce of 778 employees and holds a total market capitalization of $2.92B, reflecting its position as a mid-to-large-cap player in the specialty pharmaceutical space. The annual revenue generated over the trailing twelve months stands at $718.95M, indicating a substantial operational scale that supports ongoing R&D activities and commercialization efforts despite the company's current net loss position. These valuation metrics suggest that the market prices the stock based on future growth potential and strategic asset value rather than current profitability, a common characteristic for biopharmaceutical firms in the growth phase of their development pipeline.
Financiële gezondheid
The company reported a trailing twelve-month revenue of $718.95M, yet it recorded a net income of -$38.55M, revealing a significant divergence between top-line growth and bottom-line profitability that points to high operating expenses or restructuring costs. Despite the negative net income, the entity generated an EBITDA of $44.40M, which serves as an indicator of underlying operational cash generation before interest, taxes, depreciation, and amortization. The free cash flow stands at $55.72M, demonstrating that the company retains significant cash liquidity after capital expenditures, thereby providing financial flexibility to fund future product launches or acquisitions without immediate external financing. Margin analysis shows a gross margin of 89.6%, which is typical for pharmaceutical companies due to high R&D costs allocated to manufacturing, contrasted by a negative operating margin of -28.9% and a profit margin of -5.4%. The total cash balance of $308.67M substantially exceeds the total debt of $40.98M, resulting in a debt-to-equity ratio of 3.86, which indicates a leveraged balance sheet structure where equity financing plays a minor role relative to debt obligations. A current ratio of 1.91 suggests that the company possesses sufficient liquid assets to cover its short-term liabilities nearly twice over, ensuring robust short-term liquidity management. Furthermore, the return on equity is -3.7% and the return on assets is -2.1%, metrics that reveal that management is currently utilizing shareholder capital and assets to generate negative returns, likely due to the capital-intensive nature of drug development and commercialization.
Waarderingsbeoordeling
The trailing twelve-month P/E ratio is listed as N/A due to the lack of positive net income, whereas the forward P/E ratio is 12.01, implying that the market expects earnings to become positive in the future to justify this valuation metric. The price-to-book ratio stands at 2.74, indicating that the market values the company at a premium of 174% over its tangible book value, reflecting intangible assets like patents and drug pipelines that are not fully captured on the balance sheet. Alternative valuation metrics include a price-to-sales ratio of 4.06 and an EV/EBITDA of 59.70, suggesting that investors are pricing the stock based on sales growth potential and earnings power relative to enterprise value rather than current profitability. The stock has traded within a 52-week range with a high of $59.68 and a low of $29.16, meaning the current price sits at a specific point within this volatility band where historical price action has established support and resistance levels. The beta value is 0.73, which indicates that the stock's price volatility is approximately 27% lower than the broader market, suggesting it may serve as a defensive position relative to high-beta technology or consumer discretionary stocks during periods of market stress.
Growth & Income
Revenue growth year-over-year accelerated to 21.5%, demonstrating a strong expansion in sales volume or pricing power, while earnings growth is listed as N/A due to the current loss position, implying that top-line revenue expansion is currently outpacing any potential earnings recovery. As a non-dividend payer, the company does not distribute a dividend yield, and the payout ratio is 0.0%, indicating that the company retains all earnings or capital to reinvest into research, development, and commercialization efforts rather than returning capital to shareholders. This reinvestment strategy is characteristic of biopharmaceutical firms that prioritize funding their pipelines and expanding market share over immediate income generation for investors. The overall growth and income profile presents a scenario of high revenue expansion paired with significant cash retention and zero dividend distribution, suitable for investors seeking capital appreciation through business growth rather than yield.